Investigation of Safety and Tolerability of ASP3652 Based on Clinical Studies of Cerebrospinal Fluid Transfer After Multiple Doses and Exposure After Single Doses at High Dose Levels

• Published in: Advances in therapy Vol. 37; no. 9; pp. 3967 - 3984
• Main Authors: Takizawa, Masaomi, Cerneus, Dirk, Michon, Ingrid, Rijnders, Sanne, Meijer, John, Someya, Akiyoshi, Sato, Yuichiro
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.09.2020
• Subjects: Adolescent; Adult; Amidohydrolases - antagonists & inhibitors; Amidohydrolases - blood; Amidohydrolases - metabolism; Amidohydrolases - therapeutic use; Cardiology; Cerebrum - metabolism; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Endocrinology; Female; Healthy Volunteers; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; NCT; NCT01815684; NCT02034734; Netherlands; Oncology; Original Research; Pharmacology/Toxicology; Rheumatology; Young Adult; Netherlands; Pharmacodynamics; Endocannabinoid; Fatty acid amide hydrolase; Healthy subjects; Cerebrospinal fluid; Pharmacokinetics; Anandamide
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/s12325-020-01451-6

Introduction The studies described here were conducted to investigate the central nervous system (CNS) transfer of ASP3652, a peripherally acting inhibitor of fatty acid amide hydrolase, after multiple doses at around the anticipated therapeutic dose and the safety, tolerability, and pharmacokinetics after single doses at corresponding supratherapeutic doses in healthy subjects . Methods Study 1 was an open-label multiple dose study in which ASP3652 (300 mg bid) or matching placebo was administered in multiple doses to healthy subjects. Study 2 was a placebo-controlled, randomized 4 × 4 crossover study in which ASP3652 was given as three single ascending doses of ASP3652 (600–1800 mg) or matching placebo to healthy subjects. Levels of ASP3652 and endocannabinoids (eCBs) in plasma, cerebrospinal fluid (CSF) (study 1 only), and safety were evaluated. Results In study 1, ASP3652 was readily absorbed to reach C max at 1 h after dosing. AUC tau and C max of ASP3652 in CSF were approximately 0.2% and 0.06% of the AUC tau and C max in plasma after multiple doses of ASP3652 300 mg bid. At steady state the area under the response–time curve (AURC) from 0 to 12 h and the maximum response for anandamide in plasma were approximately 550-fold and 230-fold higher than those in CSF. In study 2, the C max and AUC of ASP3652 increased higher than dose proportionally in subjects receiving 600–1800 mg ASP3652. For eCBs, although the AURC increased less than dose proportionally, maximum plasma levels were comparable across all treatment groups. The incidence of adverse events (AEs) was similar across all treatment groups including the placebo group. There was no evidence of CNS-related side effects. Conclusions ASP3652 showed low CNS penetration at the anticipated therapeutic dose and was well tolerable without any CNS-related AEs at supratherapeutic doses, supporting that the drug can be safely tested at the anticipated therapeutic dose. Trial Registration ClinicalTrials.gov identifier, NCT02034734 for study 1, NCT01815684 for study 2.